Viruses in pharmaceutical research: Pulmonary vascular disease

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 56-64

  Reynolds, Paul N ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Adenovirus; Bone morphogenetic protein receptor; Pulmonary hypertension

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAB 9B9; IMMUNOGLOBULIN F(AB) FRAGMENT; LENTIVIRUS VECTOR; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS CAPSID ANTIGEN;

APOPTOSIS; CELL SPECIFICITY; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE PRESSURE; HETEROZYGOSITY; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LUNG ARTERY PRESSURE; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REVIEW; SEROTYPE; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; BONE MORPHOGENETIC PROTEIN RECEPTORS; GENE THERAPY; HUMANS; HYPERTENSION, PULMONARY;

EID: 79952954074     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp1003477     Document Type: Review

References (58)

1. Lee, S. D.; Shroyer, K. R.; Markham, N. E.; Cool, C. D.; Voelkel, N. F.; Tuder, R. M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. InVest. 1998, 101, 927-34. (Pubitemid 28125268)
2. Tuder, R. M. Pathology of pulmonary arterial hypertension. Semin. Respir. Crit. Care Med. 2009, 30, 376-85.
3. Badesch, D. B.; Champion, H. C; Sanchez, M. A.; Hoeper, M. M.; Loyd, J. E.; Manes, A.; McGoon, M.; Naeije, R.; Olschewski, H.; Oudiz, R. J.; Torbicki, A. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54, S55-66.
4. Barst, R. J.; Gibbs, J. S.; Ghofrani, H. A.; Hoeper, M. M.; McLaughlin, V. V.; Rubin, L. J.; Sitbon, O.; Tapson, V. F.; Galiè, N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54, S78-84.
5. Rubin, L. J.; Badesch, D. B.; Barst, R. J.; Galie, N.; Black, C. M.; Keogh, A.; Pulido, T.; Frost, A.; Roux, S.; Leconte, I.; Landzberg, M.; Simonneau, G. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002, 346, 896-903. (Pubitemid 34984638)
6. Galie, N.; Ghofrani, H. A.; Torbicki, A.; Barst, R. J.; Rubin, L. J.; Badesch, D.; Fleming, T.; Parpia, T.; Burgess, G.; Branzi, A.; Grimminger, F.; Kurzyna, M.; Simonneau, G. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005, 353, 2148-57. (Pubitemid 41653106)
7. Olschewski, H.; Simonneau, G.; Galie, N.; Higenbottam, T.; Naeije, R.; Rubin, L. J.; Nikkho, S.; Speich, R.; Hoeper, M. M.; Behr, J.; Winkler, J.; Sitbon, O.; Popov, W.; Ghofrani, H. A.; Manes, A.; Kiely, D. G.; Ewert, R.; Meyer, A.; Corris, P. A.; Delcroix, M.; Gomez-Sanchez, M.; Siedentop, H.; Seeger, W. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002, 347, 322-9. (Pubitemid 34815354)
8. Humbert, M.; Sitbon, O.; Chaouat, A.; Bertocchi, M.; Habib, G.; Gressin, V.; Yaici, A.; Weitzenblum, E.; Cordier, J. F.; Chabot, F.; Dromer, C.; Pison, C.; Reynaud-Gaubert, M.; Haloun, A.; Laurent, M.; Hachulla, E.; Cottin, V.; Degano, B.; Jais, X.; Montani, D.; Souza, R.; Simonneau, G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122, 156-63.
9. Benza, R. L.; Miller, D. P.; Gomberg-Maitland, M.; Frantz, R. P.; Foreman, A. J.; Coffey, C. S.; Frost, A.; Barst, R. J.; Badesch, D. B.; Elliott, C. G.; Liou, T. G.; McGoon, M. D. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010, 122, 164-72.
10. Lane, K. B.; Machado, R. D.; Pauciulo, M. W.; Thomson, J. R.; Phillips, J. A., 3rd; Loyd, J. E.; Nichols, W. C.; Trembath, R. C. Heterozygous germline mutations in BMPR2, encoding a TGFbeta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. 2000, 26, 81-4.
11. Deng, Z.; Morse, J. H.; Slager, S. L.; Cuervo, N.; Moore, K. J.; Venetos, G.; Kalachikov, S.; Cayanis, E.; Fischer, S. G.; Barst, R. J.; Hodge, S. E.; Knowles, J. A. Familial Primary Pulmonary Hypertension (Gene PPH1) Is Caused by Mutations in the Bone Morphogenetic Protein Receptor-II Gene. Am. J. Hum. Genet. 2000, 67, 737-744. (Pubitemid 30659603)
12. Machado, R. D.; Pauciulo, M. W.; Thomson, J. R.; Lane, K. B.; Morgan, N. V.; Wheeler, L.; Phillips, J. A., 3rd; Newman, J.; Williams, D.; Galie, N.; Manes, A.; McNeil, K.; Yacoub, M.; Mikhail, G.; Rogers, P.; Corris, P.; Humbert, M.; Donnai, D.; Martensson, G.; Tranebjaerg, L.; Loyd, J. E.; Trembath, R. C.; Nichols, W. C. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 2001, 68, 92-102. (Pubitemid 32048364)
13. Austin, E. D.; Phillips, J. A.; Cogan, J. D.; Hamid, R.; Yu, C.; Stanton, K. C.; Phillips, C. A.; Wheeler, L. A.; Robbins, I. M.; Newman, J. H.; Loyd, J. E. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res. 2009, 10, 87.
14. West, J.; Harral, J.; Lane, K.; Deng, Y.; Ickes, B.; Crona, D.; Albu, S.; Stewart, D.; Fagan, K. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am. J. Physiol. 2008, 295, L744-55.
15. West, J.; Fagan, K.; Steudel, W.; Fouty, B.; Lane, K.; Harral, J.; Hoedt-Miller, M.; Tada, Y.; Ozimek, J.; Tuder, R.; Rodman, D. M. Pulmonary hypertension in transgenic mice expressing a dominantnegative BMPRII gene in smooth muscle. Circ. Res. 2004, 94, 1109-14. (Pubitemid 38579706)
16. Song, Y.; Jones, J. E.; Beppu, H.; Keaney, J. F., Jr.; Loscalzo, J.; Zhang, Y. Y.; Kim, I. Y.; Lee, D. H.; Ahn, H. J.; Tokunaga, H.; Song, W.; Devereaux, L. M.; Jin, D.; Sampath, T. K.; Morton, R. A. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005, 112, 553-62. (Pubitemid 41060796)
17. Hong, K. H.; Lee, Y. J.; Lee, E.; Park, S. O.; Han, C.; Beppu, H.; Li, E.; Raizada, M. K.; Bloch, K. D.; Oh, S. P. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008, 118, 722-30.
18. Upton, P. D.; Morrell, N. W. TGF-beta and BMPR-II pharmacologysimplications for pulmonary vascular diseases. Curr. Opin. Pharmacol. 2009, 9, 274-80.
19. Teichert-Kuliszewska, K.; Kutryk, M. J.; Kuliszewski, M. A.; Karoubi, G.; Courtman, D. W.; Zucco, L.; Granton, J.; Stewart, D. J. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for lossof- function mutations in the pathogenesis of pulmonary hypertension. Circ. Res. 2006, 98, 209-17.
20. Machado, R. D.; Eickelberg, O.; Elliott, C. G.; Geraci, M. W.; Hanaoka, M.; Loyd, J. E.; Newman, J. H.; Phillips, J. A., 3rd; Soubrier, F.; Trembath, R. C.; Chung, W. K. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54, S32-42.
21. Atkinson, C.; Stewart, S.; Upton, P. D.; Machado, R.; Thomson, J. R.; Trembath, R. C.; Morrell, N. W. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002, 105, 1672-8. (Pubitemid 34298611)
22. Long, L.; Crosby, A.; Yang, X.; Southwood, M.; Upton, P. D.; Kim, D. K.; Morrell, N. W. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase- 5 inhibition in prevention and progression of disease. Circulation 2009, 119, 566-76.
23. Rodman, D. M.; San, H.; Simari, R.; Stephan, D.; Tanner, F.; Yang, Z.; Nabel, G. J.; Nabel, E. G. In vivo gene delivery to the pulmonary circulation in rats: transgene distribution and vascular inflammatory response. Am. J. Respir. Cell Mol. Biol. 1997, 16, 640-9. (Pubitemid 127498939)
24. Reynolds, P. N. 2002. Targeting gene delivery for pulmonary disease. In Gene therapy for diseases of the lung; Albelda, S. M., Ed.; Marcel Dekker: Vol. 169, pp 119-144.
25. Bergelson, J. M.; Cunningham, J. A.; Droguett, G.; Kurt-Jones, E. A.; Krithivas, A.; Hong, J. S.; Horwitz, M. S.; Crowell, R. L.; Finberg, R. W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275, 1320-3. (Pubitemid 27114163)
26. Waddington, S. N.; McVey, J. H.; Bhella, D.; Parker, A. L.; Barker, K.; Atoda, H.; Pink, R.; Buckley, S. M.; Greig, J. A.; Denby, L.; Custers, J.; Morita, T.; Francischetti, I. M.; Monteiro, R. Q.; Barouch, D. H.; van Rooijen, N.; Napoli, C.; Havenga, M. J.; Nicklin, S. A.; Baker, A. H. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132, 397-409. (Pubitemid 351200513)
27. Alba, R.; Bradshaw, A. C.; Parker, A. L.; Bhella, D.; Waddington, S. N.; Nicklin, S. A.; van Rooijen, N.; Custers, J.; Goudsmit, J.; Barouch, D. H.; McVey, J. H.; Baker, A. H. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114, 965-71.
28. Alba, R.; Bradshaw, A. C.; Coughlan, L.; Denby, L.; McDonald, R. A.; Waddington, S. N.; Buckley, S. M.; Greig, J. A.; Parker, A. L.; Miller, A. M.; Wang, H.; Lieber, A.; van Rooijen, N.; McVey, J. H.; Nicklin, S. A.; Baker, A. H. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010, 116, 2656-64.
29. Danilov, S. M.; Muzykantov, V. R.; Martynov, A. V.; Atochina, E. N.; Sakharov, I.; Trakht, I. N.; Smirnov, V. N. Lung is the target organ for a monoclonal antibody to angiotensin- converting enzyme. Lab. InVest. 1991, 64, 118-24.
30. Orte, C.; Polak, J. M.; Haworth, S. G.; Yacoub, M. H.; Morrell, N. W. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J. Pathol. 2000, 192, 379-84.
31. Reynolds, P. N.; Zinn, K. R.; Gavrilyuk, V. D.; Balyasnikova, I. V.; Rogers, B. E.; Buchsbaum, D. J.; Wang, M. H.; Miletich, D. J.; Douglas, J. T.; Danilov, S. M.; Curiel, D. T. A targetable injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol. Ther. 2000, 2, 562-578.
32. Reynolds, P. N. Delivery of DNA to pulmonary endothelium using adenoviral vectors. Methods Mol. Biol. 2004, 246, 69-89.
33. Giordano, R. J.; Edwards, J. K.; Tuder, R. M.; Arap, W.; Pasqualini, R. Combinatorial ligand-directed lung targeting. Proc. Am. Thorac. Soc. 2009, 6, 411-5.
34. Reynolds, P. N.; Dmitriev, I.; Curiel, D. T. Insertion of an RGD motif into the HI loop of adenovirus alters the transgene expression profile of the systemically administered vector. Gene Ther. 1999, 6, 1336-1339. (Pubitemid 29359030)
35. Izumi, M.; Kawakami, Y.; Glasgow, J. N.; Belousova, N.; Everts, M.; Kim-Park, S.; Yamamoto, S.; Wang, M.; Le, L. P.; Reynolds, P. N.; Curiel, D. T. In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J. Gene Med. 2005, 7, 1517-25. (Pubitemid 43025512)
36. Everts, M.; Kim-Park, S. A.; Preuss, M. A.; Passineau, M. J.; Glasgow, J. N.; Pereboev, A. V.; Mahasreshti, P. J.; Grizzle, W. E.; Reynolds, P. N.; Curiel, D. T. Selective induction of tumorassociated antigens in murine pulmonary vasculature using doubletargeted adenoviral vectors. Gene Ther. 2005, 12, 1042-8, Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer. (Pubitemid 40946146)
37. Nicklin, S. A.; Reynolds, P. N.; Brosnan, M. J.; White, S. J.; Curiel, D. T.; Dominiczak, A. F.; Baker, A. H. Analysis of cellspecific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 2001, 38, 65-70. (Pubitemid 34224772)
38. Reynolds, P. N.; Nicklin, S. A.; Kaliberova, L.; Boatman, B. G.; Grizzle, W. E.; Balyasnikova, I. V.; Baker, A. H.; Danilov, S. M.; Curiel, D. T. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat. Biotechnol. 2001, 19, 838-42. (Pubitemid 32816753)
39. Brunetti-Pierri, N.; Ng, P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther. 2008, 15, 553-60.
40. Flynn, R.; Buckler, J. M.; Tang, C.; Kim, F.; Dichek, D. A. Helperdependent Adenoviral Vectors are Superior In Vitro to Firstgeneration Vectors for Endothelial Cell-targeted Gene Therapy. Mol. Ther. 2010, 18 (12), 2121-9.
41. De Palma, M.; Venneri, M. A.; Naldini, L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum. Gene Ther. 2003, 14, 1193-206. (Pubitemid 36930408)
42. Morizono, K.; Pariente, N.; Xie, Y.; Chen, I. S. Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J. Gene Med. 2009, 11, 549-58.
43. Pariente, N.; Mao, S. H.; Morizono, K.; Chen, I. S. Efficient targeted transduction of primary human endothelial cells with dualtargeted lentiviral vectors. J. Gene Med. 2008, 10, 242-8. (Pubitemid 351368991)
44. Romano, G.; Marino, I. R.; Pentimalli, F.; Adamo, V.; Giordano, A. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients. Drug News Perspect. 2009, 22, 185-96.
45. Suhara, H.; Sawa, Y.; Fukushima, N.; Kagisaki, K.; Yokoyama, C.; Tanabe, T.; Ohtake, S.; Matsuda, H. Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. J. Thorac. CardioVasc. Surg. 2002, 123, 855-61.
46. Ono, M.; Sawa, Y.; Fukushima, N.; Suhara, H.; Nakamura, T.; Yokoyama, C.; Tanabe, T.; Matsuda, H. Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats. Eur. J. Cardiothorac. Surg. 2004, 26, 1092-7. (Pubitemid 39487453)
47. Nagaya, N.; Yokoyama, C.; Kyotani, S.; Shimonishi, M.; Morishita, R.; Uematsu, M.; Nishikimi, T.; Nakanishi, N.; Ogihara, T.; Yamagishi, M.; Miyatake, K.; Kaneda, Y.; Tanabe, T. Gene transfer of human prostacyclin synthase ameliorates monocrotaline- induced pulmonary hypertension in rats. Circulation 2000, 102, 2005-10.
48. Miller, W. H.; Brosnan, M. J.; Graham, D.; Nicol, C. G.; Morecroft, I.; Channon, K. M.; Danilov, S. M.; Reynolds, P. N.; Baker, A. H.; Dominiczak, A. F. Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Mol. Ther. 2005, 12, 321-7. (Pubitemid 41025103)
49. Reynolds, A. M.; Xia, W.; Holmes, M. D.; Hodge, S. J.; Danilov, S.; Curiel, D. T.; Morrell, N. W.; Reynolds, P. N. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am. J. Physiol. 2007, 292, L1182-92. (Pubitemid 47084862)
50. Reynolds, A. M.; Holmes, M.; Morrell, N. W.; Danilov, S.; Reynolds, P. N. Gene delivery of bone morphogenetic protein receptor type-2 attenuates established hypoxic and monocrotalineinduced pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2010, 181, A6333.
51. McMurtry, M. S.; Moudgil, R.; Hashimoto, K.; Bonnet, S.; Michelakis, E. D.; Archer, S. L. Overexpression of human bone morphogenetic protein receptor II does not ameliorate monocrotaline pulmonary arterial hypertension. Am. J. Physiol. 2007, 292 (4), L872-8. (Pubitemid 46608233)
52. Nakaoka, T.; Gonda, K.; Ogita, T.; Otawara-Hamamoto, Y.; Okabe, F.; Kira, Y.; Harii, K.; Miyazono, K.; Takuwa, Y.; Fujita, T. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J. Clin. InVest. 1997, 100, 2824-32. (Pubitemid 28007552)
53. Vieillard-Baron, A.; Frisdal, E.; Eddahibi, S.; Deprez, I.; Baker, A. H.; Newby, A. C.; Berger, P.; Levame, M.; Raffestin, B.; Adnot, S.; d'Ortho, M. P. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ. Res. 2000, 87, 418-25.
54. Vieillard-Baron, A.; Frisdal, E.; Raffestin, B.; Baker, A. H.; Eddahibi, S.; Adnot, S.; D'Ortho, M. P. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline- induced pulmonary vascular remodeling in rats. Hum. Gene Ther. 2003, 14, 861-9. (Pubitemid 36693795)
55. McMurtry, M. S.; Archer, S. L.; Altieri, D. C.; Bonnet, S.; Haromy, A.; Harry, G.; Puttagunta, L.; Michelakis, E. D. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. InVest. 2005, 115, 1479-91. (Pubitemid 40814657)
56. Kamezaki, F.; Tasaki, H.; Yamashita, K.; Tsutsui, M.; Koide, S.; Nakata, S.; Tanimoto, A.; Okazaki, M.; Sasaguri, Y.; Adachi, T.; Otsuji, Y. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 2008, 177, 219-26.
57. Pozeg, Z. I.; Michelakis, E. D.; McMurtry, M. S.; Thebaud, B.; Wu, X. C.; Dyck, J. R.; Hashimoto, K.; Wang, S.; Moudgil, R.; Harry, G.; Sultanian, R.; Koshal, A.; Archer, S. L. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003, 107, 2037-44. (Pubitemid 36506080)
58. Farkas, L.; Farkas, D.; Ask, K.; Moller, A.; Gauldie, J.; Margetts, P.; Inman, M.; Kolb, M. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J. Clin. InVest. 2009, 119, 1298-311.